Chongqing Lummy Pharmaceutical (300006) — Working Capital to Net Assets Ratio
Chongqing Lummy Pharmaceutical (300006) has a Working Capital to Net Assets ratio of 46.0% as of September 2025. Working capital of CN¥852.78 Million (current assets of CN¥1.67 Billion minus current liabilities of CN¥818.45 Million) is measured against net assets of CN¥1.85 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 300006 net asset quality index to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Chongqing Lummy Pharmaceutical Working Capital to Net Assets (2006–2024)
This chart shows how Chongqing Lummy Pharmaceutical's Working Capital to Net Assets ratio has evolved across 19 annual periods from 2006 to 2024. As of September 2025, the ratio stands at 46.0%, reflecting working capital of CN¥852.78 Million against net assets of CN¥1.85 Billion CNY. Check tangible net worth ratio of Chongqing Lummy Pharmaceutical to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Chongqing Lummy Pharmaceutical (2006–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Chongqing Lummy Pharmaceutical from 2006 to 2024, covering 19 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 300006 company net worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 51.4% | CN¥968.49 Million | CN¥1.88 Billion | CN¥1.77 Billion | CN¥801.61 Million | ▲ +0.3 pp |
| 2023 | 51.1% | CN¥1.08 Billion | CN¥2.12 Billion | CN¥1.65 Billion | CN¥562.27 Million | ▲ +3.3 pp |
| 2022 | 47.8% | CN¥1.04 Billion | CN¥2.18 Billion | CN¥1.75 Billion | CN¥701.14 Million | ▼ -0.1 pp |
| 2021 | 47.9% | CN¥1.06 Billion | CN¥2.21 Billion | CN¥1.73 Billion | CN¥666.80 Million | ▲ +48.3 pp |
| 2020 | -0.4% | CN¥-4.58 Million | CN¥1.23 Billion | CN¥1.70 Billion | CN¥1.70 Billion | ▼ -3.3 pp |
| 2019 | 2.9% | CN¥48.36 Million | CN¥1.65 Billion | CN¥1.78 Billion | CN¥1.73 Billion | ▼ -1.3 pp |
| 2018 | 4.2% | CN¥72.86 Million | CN¥1.72 Billion | CN¥1.29 Billion | CN¥1.21 Billion | ▼ -10.2 pp |
| 2017 | 14.5% | CN¥249.39 Million | CN¥1.72 Billion | CN¥1.08 Billion | CN¥832.71 Million | ▼ -1.8 pp |
| 2016 | 16.3% | CN¥272.93 Million | CN¥1.67 Billion | CN¥891.49 Million | CN¥618.56 Million | ▼ -4.3 pp |
| 2015 | 20.6% | CN¥348.07 Million | CN¥1.69 Billion | CN¥1.56 Billion | CN¥1.21 Billion | ▲ +52.5 pp |
| 2014 | -31.9% | CN¥-323.97 Million | CN¥1.02 Billion | CN¥728.29 Million | CN¥1.05 Billion | ▼ -28.9 pp |
| 2013 | -3.0% | CN¥-33.85 Million | CN¥1.13 Billion | CN¥914.65 Million | CN¥948.50 Million | ▲ +5.4 pp |
| 2012 | -8.4% | CN¥-59.41 Million | CN¥710.51 Million | CN¥629.05 Million | CN¥688.46 Million | ▼ -18.9 pp |
| 2011 | 10.5% | CN¥69.49 Million | CN¥660.17 Million | CN¥472.62 Million | CN¥403.13 Million | ▼ -22.0 pp |
| 2010 | 32.6% | CN¥182.81 Million | CN¥561.59 Million | CN¥486.40 Million | CN¥303.59 Million | ▼ -51.1 pp |
| 2009 | 83.7% | CN¥439.27 Million | CN¥525.08 Million | CN¥567.81 Million | CN¥128.55 Million | ▲ +45.2 pp |
| 2008 | 38.5% | CN¥53.00 Million | CN¥137.79 Million | CN¥183.77 Million | CN¥130.77 Million | ▲ +5.3 pp |
| 2007 | 33.2% | CN¥35.83 Million | CN¥107.91 Million | CN¥142.60 Million | CN¥106.78 Million | ▲ +2.3 pp |
| 2006 | 30.9% | CN¥19.92 Million | CN¥64.39 Million | CN¥80.64 Million | CN¥60.72 Million | — |